NR3C2 and heart failure: Specifically, the early introduction of GDMT to these patients, which involves the initiation and titration of pharmacological agents, including angiotensin converting enzyme-inhibitors, angiotensin II receptor blockers, angiotensin receptor neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose co-transporter-2 inhibitors, has been shown to reduce mortality and heart failure related hospitalizations [10,11,12].